This site uses cookies

To give you the best possible experience, the GAM website uses cookies. You can read full information of our cookie use here. Your privacy is important to us and we encourage you to read our privacy policy here.

OK
Press Release

GAM wins biotechnology advisory agreement in Taiwan

Wednesday, June 20, 2018

GAM Investments today announced that it has been awarded a USD 200 million advisory agreement from First Securities Investment Trust Co. Ltd (FSITC), a wholly owned subsidiary of First Financial Group, a publicly listed company on the Taiwan stock exchange. The advisory agreement will have a specific focus on medical innovation driven by advances in artificial intelligence (AI), as well as precision medicine and will be managed by Christophe Eggmann, portfolio manager for healthcare equities at GAM.

The strategy seeks to provide long term capital growth by investing globally in innovation-driven companies active in all healthcare sub-sectors, including pharmaceuticals, biotechnology, healthcare services and supplies, medical technology as well as specialty pharmaceuticals and generics.

Christophe Eggmann, portfolio manager at GAM, said: “Today, the healthcare sector knows more about diseases and targets and has better tools to design targeted drugs than ever before. Therefore, there has never been a better time to invest in healthcare innovation. Innovation is at the core of every investment decision we make and remains the most important driver of growth and value creation.”

Tommy Chang, portfolio manager at FSITC, said: “AI precision medicine combines a wide range of technologies, facilitating faster treatment and advancing the entire medical sequence from disease prevention to diagnosis, treatment and aftercare. The strategy allows us to capture this innovation potential in our portfolio.”

Rossen Djounov, head of GAM Asia, said: “We are honoured to be selected by FSITC and look forward to working closely with them to achieve their investment goals. This win is testimony to our investment management team’s deep knowledge and understanding of the healthcare sector. We continue to see strong interest in our product offering across Asia as we grow in the region.”

 

For more information, please contact:

GAM Media Relations:
London: +44 (0) 207 393 86 99

Follow us on: TwitterLinkedIn

About GAM

GAM is one of the world’s leading independent, pure-play asset managers. The company provides active investment solutions and products for institutions, financial intermediaries and private investors. The core investment business is complemented by private labelling services, which include management company and other support services to third-party asset managers. GAM employs over 900 people in 13 countries with investment centres in London, Cambridge, Zurich, Hong Kong, New York, Milan and Lugano. The investment managers are supported by an extensive global distribution network.

Headquartered in Zurich, GAM is listed on the SIX Swiss Exchange and is a component of the Swiss Market Index Mid (SMIM) with the symbol ‘GAM’. The Group has assets under management of CHF 162.3 billion (USD 169.4 billion)*.

*Source: GAM. Data as at 31 March 2018.
Important legal information

The information in this document is given for information purposes only and does not qualify as investment advice. Opinions and assessments contained in this document may change and reflect the point of view of GAM in the current economic environment. No liability shall be accepted for the accuracy and completeness of the information. Past performance is no indicator for the current or future development.

Scroll to top